We evaluated the effect of chronic bovine growth hormone treatment on the hepatic somatotropic receptor. Growing lambs were treated with bGH at 0, 0.05, 0.15, 0.25 or 0.55 mg.kg-1.day-1 daily (N = 5/group) for 56 days. The binding of ovine GH to hepatic membranes washed with 4 mol/l MgCl2 and prepared in the presence of aprotinin was examined. The specific binding of oGH was increased (p less than 0.01) from 7.1 +/- 1.2% in saline-treated controls to 17.4 +/- 1.5% in the 0.55 mg.kg-1.day-1 group. Scatchard analysis showed curvilinear plots that best fitted a two-site model in 22/25 livers. The two sites had estimated dissociation constants (Kd) of 3 to 13 nmol/l for the low-affinity site and a Kd ranging from 0.17 to 0.31 nmol/l for the high-affinity site. Treatment with bGH had no consistent effect on the affinity of either binding site. However, bGH therapy was associated with a dose-dependent increase (p less than 0.01) in the number of high-affinity somatotropic receptors. There was no effect of bGH therapy on the concentration of low-affinity binding sites. The concentration of high-affinity receptors correlated with weight gain (r = 0.54, p less than 0.01), fat content (r = -0.54, p less than 0.01), protein content (r = 0.40, p less than 0.05), and plasma IGF-I (r = 0.57, p less than 0.005). The concentrations of low-affinity binding sites showed no such correlations.(ABSTRACT TRUNCATED AT 250 WORDS)